Pleiotropic effects of atorvastatin in rheumatoid arthritis patients with no history of cardiovascular diseases

Terapevticheskii Arkhiv

Volumn 87, Issue 9, 2015, Pages 72-75

  Smakotina, S A ^a   Zelendinova, A R ^a   Bondareva, I N ^b   Berns, S A ^c  

^a KEMEROVO STATE MEDICAL UNIVERSITY   (Russian Federation)

^b N N BLOKHIN NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY   (Russian Federation)

^c A I EVDOKIMOV MOSCOW STATE UNIVERSITY OF MEDICINE AND DENTISTRY   (Russian Federation)

Author keywords

Rheumatoid arthritis; Statins; Systemic inflammation

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; HYPOCHOLESTEROLEMIC AGENT; IL6 PROTEIN, HUMAN; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RHEUMATOID FACTOR; STROMELYSIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTHRITIS, RHEUMATOID; BLOOD; CARDIOVASCULAR DISEASES; DRUG EFFECTS; FEMALE; HUMAN; INFLAMMATION; LIPID METABOLISM; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PATIENT ACUITY; TREATMENT OUTCOME;

ADULT; ANTICHOLESTEREMIC AGENTS; ARTHRITIS, RHEUMATOID; ATORVASTATIN CALCIUM; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-6; LIPID METABOLISM; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; PATIENT ACUITY; RHEUMATOID FACTOR; TREATMENT OUTCOME; TRIGLYCERIDES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84957792488     PISSN: 00403660     EISSN: None     Source Type: Journal    
DOI: 10.17116/terarkh201587972-76     Document Type: Article

References (24)

1. Peters MJ, Symmons DP, McCarey DW et al. EULAR evidencebased recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other types of inflammatory arthritis -TASK FORCE Cardiovascular risk management in RA. Ann Rheum Dis. 2010;69(2): 325-331.
2. Van Halm VP, Peters MJ, Voskuyl AE et al. Rheumatoid arthritis versus type 2 diabetes as a risk factor for cardiovascular disease: A cross-sectional study. Ann Rheum Dis. 2009;68: 1395-1400.
3. Maradit-Kremers H, Crowson CS, Therneau TM et al. High tenyear risk of cardiovascular disease in newly diagnosed rheumatoid arthritis patients. A population-based cohort study. Arthr Rheum. 2008;58(8): 2268-2274.
4. Goodson NI, Willes NJ, Lunt NC. Mortality on early inflamatory arthritis: Cardiovascular mortality in seropositive patients. Arthr Rheum. 2002;46: 2010-2019.
5. Gonzalez-Gay MA, Gonzalez-Juanatey C, Martin J. Rheumatoid arthritis: A disease associated with accelerated atherogenesis. Semin Arthr Rheum. 2005;35: 8-17.
6. Gerli R, Bartoloni Bocci E, Sherer Y et al. Association of anticyclic citrullinated peptide antibodies with subclinical atherosclerosis in patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67: 724-725.
7. Lopez-Longo FJ, Oliver-Minarro D, de la Torre I et al. Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthr Rheum. 2009;61: 419-424.
8. Meune C, Touze E, Trinqurte L et al. Trends in cardiovascular mortality in patients with rheumatoid arthritis over 50 years: A systematic review and meta-Analisis of cohort studies. Rheumatology. 2009;48(10): 1309-1313.
9. Gazi IF, Boumpas DT, Mikhailidis DP et al. Clustering of cardiovascular risk factors in rheumatoid arthritis: The rationale for using statins. Clin Exp Rheum. 2007;25: 102-111.
10. Bisoendial R, Stroes E, Kastelein J, Tak P. Targeting cardiovascular risk in rheumatoid arthritis: A dual role for statins. Nat Rev Rheum. 2010. doi: 10.1038/nrrheum.2009.277.
11. Nurmohamed M, Dijkmans B. Dyslipidemia, statins and rheumatoid arthritis. Ann Rheum Dis. 2009;68: 453-455.
12. Nielen MJ, van Halm VP, Nurmohamed MT et al. Rheumatoid arthritis is preceded by a preclinical phase, characterized by increased C-reactive protein levels and a more atherogenic lipid profile. Arthr Rheum. 2003;48: 344.
13. Van Halm VP, Nielen MJ, Nurmohamed MT et al. Lipids and inflammation: Serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann Rheum Dis. 2006;3: 1-5.
14. Myasoedova E, Gabriel S. Cardiovascular disease in rheumatoid arthritis: A step forward. Curr Opin Rheumatol. 2010;22: 342-347.
15. Bisoendial R, Stroes E, Kastelein J, Tak P. Targeting cardiovascular risk in rheumatoid arthritis: A dual role for statins. Nat Rev Rheum. 2010. doi: 10.1038/nrrheum.2009.277.
16. Curtis J, John A, Baser O et al. Frequency of lipid testing in patients with rheumatoid arthritis: A retrospective database analysis. Arthr Rheum. 2009;60(Suppl. 10): S516.
17. Toms TE, Panoulas VF, Douglas KM et al. Statin use in rheumatoid arthritis in relation to actual cardiovascular risk: Evidence for substantial under treatment of lipid associated cardiovascular risk Ann Rheum Dis. 2009;Oct 23 [Epub. ahead of print].
18. Okamoto H, Koizumi K, Kamitsuji S et al. Beneficial action of statins in patients with rheumatoid arthritis in a large observational cohort. J Rheumatol. 2007;34: 964-968. http://www.cardiosite.ru.
19. Lindhardsen J, Ahlehoff O, Gislason G, Madsen OR, Olesen JB, Pedersen CT, Hansen PR. The risk of miocardial infarction in rheumatoid arthritis and diabetes mellitus: A Danich nationwide cohort study. Ann Rheum Dis. 2011;70: 929-934. doi: 10.1136/ard.2010.1433.
20. Charles-Schoeman C, Khanna D, Furst DE et al. Effects of highdose atorvastatin on anti-inflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: A pilot study. J Rheumatol. 2007;34(7): 1458-1464.
21. Lien LM, Hsieh YC. Association of blood active matrix metalloproteinase-3 with carotid plaque score from a community population in Taiwan. Atherosclerosis. 2010;212(2): 595-600.
22. Nissen SE, Tuzcu EM, Schoenhagen P et al. REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial. JAMA. 2004;291(9): 1071-1080.
23. Cannon CP, Braunwald E, Mc. Cabe CH et al. Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350: 15-24.
24. Khush KK, Waters D. Higher dose of potent statin better for highrisk patients. Cleveland Clin J Med. 2004;1: 609-616.